Princeton University Logo

Princeton University Graduate Consulting Club Case Competition

Event date: June 22, 2018

Back Bay Senior Consultant, Tejdeep Singh Bawa has been invited for the second year to mentor, judge, and guide members of Princeton’s University Graduate Consulting Club through the 2018 PuGCC Case Competition.

On June 22, 2018 twenty-four teams of graduate and professional students interested in management consulting will show their expertise and creative thinking and learn high-level consulting skills from seasoned experts in the field, including Back Bay Life Science Advisors, McKinsey & Company, Accenture, and Boston Consulting Group.

2018 ASCO Annual Meeting

Back Bay at Annual meeting of the American Society of Clinical Oncology (ASCO)

/ ASCO, Cancer, Oncology

Event date: June 1-5, 2018

Back Bay joined the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, where thousands of oncology professionals from around the world gathered to share the latest approaches to cancer care.

BIO2018 Banner

Back Bay Welcomes the BIO International Convention to Boston

Event date: June 4-7, 2018

The Back Bay team, led by Chris Leo, Greg Benning, and Vasilios M. Kofitsas welcomed the 2018 Bio International Convention to our hometown of Boston. Boston’s trajectory as a biotech leader has been remarkable, and we’re proud to be part of the biotech and med tech evolution here. BIO brings together thousands from biopharma, med tech and more for collaborative discussion, networking and partnering opportunities.


Immunotherapies white paper

Back Bay Report on Neoantigen-Based Cancer Immunotherapy

By Jonathan P. Gertler, MD

Immuno-oncology, a promise for decades, has burst forth as a clear means to advance patient care and spur research and development. Science and industry are working fervently to untangle this data-heavy, rapidly-evolving field and bring effective IO combinations to more patients. As positive data and widespread support accumulate for the potential checkpoint inhibitors and neoantigens in numerous challenging and refractory cancers, hundreds of trials are being implemented that seek to increase efficacy and bring these novel therapeutics to more patients in critical need.


back bay life science advisors logo

Asia Opens Its Doors for Pre-Revenue Biotechs

/ Biotech
By Ned Benning, Analyst, Back Bay Life Science Advisors

One of the primary axioms at Back Bay Life Science Advisors is that assets must find the right form of capital. Venture is not right for every academic-derived technology. Going public is not right for every growing company or late-stage biotech. Geographic variation can bring different timelines, different IRR hurdles, and different ecosystem mandates. Capital sources are forever shifting, and lately, investment from China has been looming large on the radar screen for U.S. biotech. We see this as a good thing. (more…)

Transcatheter Mitral Valve Technologies: The Heart of Cardiovascular Device Innovation

Transcatheter Mitral Valve Technologies: The Heart of Cardiovascular Device Innovation

By Tejdeep Singh Bawa, Michelle Hoffmann, Susan Thompson, Stephanie Kwei

Medical device companies developing next-generation mitral valve repair and replacement technologies have generated unprecedentedly high valuations at ever-earlier stages of device development. Medtech investors are acquiring early-stage transcatheter mitral valve technologies long before commercialization and even before critical clinical data is amassed.


BIO2018 Banner

Back Bay CEO Selected as Judge for BIO 2018 Start-Up Stadium

RE: Jonathan P. Gertler

Boston, May 1, 2018—Back Bay Life Science Advisors, strategic and transactional advisors to the life science industry, announced today that Jonathan P. Gertler, Managing Partner and CEO, has been selected to judge the Start-up Stadium competition at the upcoming BIO International Convention (BIO 2018) June 4-7 in Boston.


Bloomberg Logo

Back Bay CEO and Denmark’s Consul General Interviewed on Bloomberg Radio about the Boston and Denmark Biotech Ecosystems

RE: Jonathan P. Gertler

Bloomberg’s Anne Mostue spoke with Dr. Jonathan Gertler of Back Bay Life Sciences Advisors and Anne Dorte Riggelsen, Denmark’s Consul General in New York, about the synergies between Denmark and Boston in the life sciences field.

Listen to the Bloomberg interview here


transactional trends header image

2018 Transactional Trends: Key Issues for Cross-Border Deals; Focus on Emerging and Mid-Size Companies

By Greg Benning

Back Bay Life Science Advisors recently co-hosted DKBIO 2018: Danish Science & The City at Harvard Medical School focused on cross-border investment and transactions in the life sciences sector.

Back Bay’s M&A team presented information on the IPO, M&A and Venture markets, with a specific focus on mid-size companies, that finds clear shifts in money flow, M&A, IPOs, and VC investing volumes, as well as top-10 rankings.

Back Bay Life Science Advisors to Lead Fireside Chat with Myovant Sciences President & Chief Executive Officer, Lynn Seely at Convergence Forum 2018

Back Bay Life Science Advisors will again serve as a lead sponsor for the Convergence Forum. On May 11, Back Bay CEO Jonathan Gertler will host a discussion with former Medivation Founder and current Myovant Sciences President & Chief Executive Officer, Lynn Seely.